at www.tipranks.com (Tue, 10-Nov 8:10 AM)
Cantor Fitzgerald Sticks to Their Buy Rating for AbCellera Biologics (ABCL)
at www.tipranks.com (Tue, 10-Nov 7:56 AM)
Wall Street Analysts Are Bullish on Top Healthcare Picks
at www.tipranks.com (Tue, 10-Nov 7:50 AM)
AbCellera Biologics GAAP EPS of -$0.13 beats by $0.05, revenue of $10.6M beats by $4.35M
at seekingalpha.com (Mon, 9-Nov 4:19 PM)
Here are the major earnings after the close Monday
at seekingalpha.com (Mon, 9-Nov 10:00 AM)
AbCellera Biologics Q3 2026 Earnings Preview
at seekingalpha.com (Sun, 8-Nov 5:35 PM)
at seekingalpha.com (Sun, 8-Nov 10:00 AM)
ABCL Spotlight: Phase 2 Data Show ABCL635 Cut Vasomotor Symptoms by 8.8 Per Day at Week Four
Market Chameleon (Thu, 22-Oct 7:12 AM)
Market Chameleon (Fri, 9-Oct 7:55 AM)
AbCellera sets November 9 date for Q3 2026 results and a 3:00 p.m. Pacific earnings call
Market Chameleon (Fri, 2-Oct 9:04 AM)
AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data
Market Chameleon (Thu, 17-Sep 7:10 AM)
Market Chameleon (Wed, 19-Aug 9:16 AM)
AbCellera’s Strong Phase 2 Data Spotlight New Highs and Next Steps for ABCL635
Market Chameleon (Wed, 12-Aug 7:07 AM)
ABCL Phase 2 Results Spark Renewed Interest: 83% Reduction in Vasomotor Symptoms Stands Out
Market Chameleon (Tue, 11-Aug 11:21 AM)
Market Chameleon (Mon, 10-Aug 10:31 AM)
Market Chameleon (Mon, 10-Aug 7:06 AM)
